ArticleUpdates in surgery2025
Ultrasound-guided radiofrequency ablation for isthmus papillary thyroid microcarcinoma: a prospective 2 years of follow-up study.
Article in Updates in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Thermal ablation for papillary thyroid carcinoma in the isthmus: a systematic review and meta-analysis.Gland surgery · 2025Article
- Thermal ablation for papillary thyroid microcarcinoma in the isthmus: a systematic review and meta-analysis.Endocrine connections · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
To explore the safety and clinical efficacy of radiofrequency ablation (RFA) for papillary thyroid microcarcinoma (PTMC) located in the isthmus. This prospective study enrolled patients with single isthmus PTMC admitted to General Surgery Department of 983rd Hospital of Joint Logistic Support Force of PLA from 2017 to 2022. After ablation, the ultrasound and contrast-enhanced ultrasound (CEUS) were performed to follow up the outcomes at 1, 3, 6, 12, 18, and 24 months. The volume reduction rates (VRR), disappearance rates (DR), incidence of complications, recurrence, and lymph node metastasis were recorded. A total of 135 patients were enrolled in this study, including 26 men and 109 women. The average age was 41.07±13.60 years old. The average diameter of PTMC was 0.68 ±0.17cm. After ablation, the DRs at 1, 3, 6, 12, 18 months, and 24 months were 0.0% (0/135), 10.4% (14/135), 52.6% (71/135), 81.5% (110/135), 100% (135/135), and 100% (135/135), and the VRRs at 1, 3, 6, 12, 18 months, and 24 months were 66.18±12.57%, 82.42±12.01%, 93.33±8.70%, 98.58±3.71%, 100.00±0.00%, 100.00±0.00%. Two patients suffered recurrence of PTMC in the thyroid at 6 and 12 months after ablation, and one patient suffered cervical lymph node metastases at 18 months after ablation. No patient had serious complications, including death, hemorrhage, or thermal injury to peripheral organs. RFA was a safe and effective treatment for isthmus PTMC, which may add new choices to the treatment strategy for patients.
Indexed as
Identifiers
39865211What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.